| Item Type | Name |
|
Concept
|
Enzyme Inhibitors
|
|
Concept
|
Angiogenesis Inhibitors
|
|
Concept
|
Aromatase Inhibitors
|
|
Concept
|
Protein Kinase Inhibitors
|
|
Academic Article
|
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
|
|
Academic Article
|
Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.
|
|
Academic Article
|
A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer.
|
|
Academic Article
|
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
|
|
Academic Article
|
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
|
|
Academic Article
|
Phase II trial of temsirolimus in patients with metastatic breast cancer.
|
|
Academic Article
|
Phase II evaluation of thalidomide in patients with metastatic breast cancer.
|
|
Academic Article
|
Adjuvant aromatase inhibitors: are we there yet?
|
|
Academic Article
|
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
|
|
Academic Article
|
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.
|
|
Academic Article
|
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
|
|
Academic Article
|
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
|
|
Academic Article
|
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.
|
|
Academic Article
|
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
|
|
Academic Article
|
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
|
|
Academic Article
|
Adjuvant ovarian suppression in premenopausal breast cancer.
|
|
Academic Article
|
Adjuvant ovarian suppression in premenopausal breast cancer.
|
|
Academic Article
|
New drugs in ovarian cancer.
|
|
Academic Article
|
Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma.
|
|
Academic Article
|
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.
|
|
Academic Article
|
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
|
|
Academic Article
|
Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma.
|
|
Academic Article
|
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
|
|
Academic Article
|
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
|
|
Academic Article
|
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
|
|
Academic Article
|
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
|
|
Academic Article
|
Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations.
|
|
Academic Article
|
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
|
|
Academic Article
|
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.
|
|
Concept
|
Poly(ADP-ribose) Polymerase Inhibitors
|
|
Concept
|
Cytochrome P-450 Enzyme Inhibitors
|
|
Academic Article
|
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
|
|
Academic Article
|
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
|